# Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

> **NCT02228304** · PHASE1,PHASE2 · TERMINATED · sponsor: **Neurotech Pharmaceuticals** · enrollment: 42 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** NT-503-3 ECT implantation
- **DRUG:** Eylea® injected intravitreally administered every 8 weeks

## Key facts

- **NCT ID:** NCT02228304
- **Lead sponsor:** Neurotech Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** After enrolling approximately 1/2 of the trial participants, the rescues exceeded stopping criteria.
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02228304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02228304, "Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02228304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*